Chiesi Group to Acquire KalVista Pharmaceuticals in $1.9 Billion Deal

Chiesi Group has reached an agreement to purchase KalVista Pharmaceuticals for approximately $1.9 billion, paying $27.00 per share in cash. This acquisition is intended to bolster Chiesi's rare immunology offerings by integrating KalVista's oral therapy for hereditary angioedema. Both companies' boards have approved the transaction, which is anticipated to finalize in the third quarter of 2026.